S&P Futures
3,828.00 +2.50 (+0.07%) Dow Futures
30,955.00 +22.00 (+0.07%) Nasdaq Futures
11,683.25 +9.00 (+0.08%) Russell 2000 Futures
1,739.40 +1.10 (+0.06%) Crude Oil
111.40 -0.36 (-0.32%) Gold
1,823.20 +2.00 (+0.11%)
TransCode Therapeutics, Inc. Common Stock (RNAZ)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.3350 |
| Open | 1.2945 |
| Bid | 1.2100 x 3100 |
| Ask | 1.2900 x 1400 |
| Day's Range | 1.2501 - 1.3600 |
| 52 Week Range | 1.1500 - 7.0000 |
| Volume | |
| Avg. Volume | 40,851 |
| Market Cap | 16.621M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7620 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
- GlobeNewswire
TransCode Therapeutics to Participate at BIO International Convention
BOSTON, June 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the BIO International Convention to be held June 13-16 in San Diego, CA. The in-person venue for the event is the San Diego Convention Center. During the presentation, TransCode’s Chief Executive Officer, Michael Dudley, will discuss the Company's RNA-based scientific discoveries that it believes have the potential to significantly advance the treatmen
- GlobeNewswire
TransCode Therapeutics Receives National Institutes of Health (NIH) Notice of Award
Funding is part of a 2021 Fast-Track Small Business Innovation Research (SBIR) grant to Support Clinical Development of First-in-Class Therapy for Advanced Solid Tumors First SBIR program milestone achieved in Q1 2022 BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced that it was awarded the second tranche of funding from a Fast-Track Small Business Innovation Resear
- GlobeNewswire
TransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference
BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the H.C. Wainwright Global Investment Conference. The in-person venue for the hybrid event is the Fontainebleau Hotel in Miami Beach at 4441 Collins Avenue. Virtual participation will be staged simultaneously as a live feed and available on-demand. During the presentation, TransCode’s Chief Executive Officer, Michael Dudley, will discuss the Company's RNA-based scien
